David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.

• 1. Cancer Terminator Viruses and Approaches for Enhancing Therapeutic Outcomes2. Targeted Ad3. Syrian hamster as an animal model for oncolytic adenoviruses and for the study of adenoviral pathogenesis4. Design of improved oncolytic adenoviruses5. Imaging of a Somatostatin Receptor-Cytosine Deaminase Fusion Gene6. Diz Detection7. Adenovirus-based immunotherapies for cancer8. Toxin GT9. Radiation Therapy/ Gene Therapy10. Cell Vehicles11. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters and humans

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.

• 1. Cancer Terminator Viruses and Approaches for Enhancing Therapeutic Outcomes2. Targeted Ad3. Syrian hamster as an animal model for oncolytic adenoviruses and for the study of adenoviral pathogenesis4. Design of improved oncolytic adenoviruses5. Imaging of a Somatostatin Receptor-Cytosine Deaminase Fusion Gene6. Diz Detection7. Adenovirus-based immunotherapies for cancer8. Toxin GT9. Radiation Therapy/ Gene Therapy10. Cell Vehicles11. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters and humans

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.

• 1. Cancer Terminator Viruses and Approaches for Enhancing Therapeutic Outcomes2. Targeted Ad3. Syrian hamster as an animal model for oncolytic adenoviruses and for the study of adenoviral pathogenesis4. Design of improved oncolytic adenoviruses5. Imaging of a Somatostatin Receptor-Cytosine Deaminase Fusion Gene6. Diz Detection7. Adenovirus-based immunotherapies for cancer8. Toxin GT9. Radiation Therapy/ Gene Therapy10. Cell Vehicles11. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters and humans